Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3BCHECHRM1CHRM2CHRM3CHRM4CHRNA3CHRNA4CHRNB2CHRNB4ESR1ESR2GABRA1GABRB1GABRG2GBA1GHSRHRH1HTR1DHTR2AMAOBOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8UGCGrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL224857 | 0.96 | TSHR (0.47) | TSHRLMNACA4CYP3A4TDP1 | |
| Cadaverine Tartrate SCHEMBL15206510 | 0.92 | LMNA (0.48) | TSHRLMNACA4CYP3A4TDP1 | |
| Cadaverine Tartrate SCHEMBL8764752 | 0.92 | TSHR (0.44) | TSHRLMNACA4CYP3A4TDP1 | |
| Cadaverine Tartrate SCHEMBL4726194 | 0.92 | TSHR (0.44) | TSHRLMNACA4CYP3A4TDP1 | |
| Cadaverine Tartrate SCHEMBL8928612 | 0.92 | TSHR (0.44) | TSHRLMNACA4CYP3A4TDP1 | |
| Cadaverine Tartrate SCHEMBL25339362 | 0.92 | TSHR (0.44) | TSHRLMNACA4CYP3A4TDP1 | |
| Cadaverine Tartrate SCHEMBL6570820 | 0.89 | LMNA (0.46) | TSHRLMNACA4CYP3A4TDP1 | |
| Cadaverine Tartrate SCHEMBL11731581 | 0.89 | CA4 (0.47) | TSHRLMNACA4CYP3A4TDP1 | |
| Cadaverine Tartrate SCHEMBL3591252 | 0.88 | TSHR (0.47) | TSHRLMNACA4CYP3A4TDP1 | |
| Cadaverine Tartrate SCHEMBL813951 | 0.88 | TSHR (0.47) | TSHRLMNACA4CYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 957 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4103144-B1 | COMPOSITIONS COMPRISING UV-FILTERS AND ONE OR MORE (BIO)-ALKANEDIOLS | SYMRISE AG (DE) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026087745-A1 | AN ANTIOXIDANT COMPOSITION COMPRISING A CINNAMIC ACID DERIVATIVE | BRAIN Biotech AG (DE) | 2026-04-30 | — | — | WO | disclosed |
| EP-4732825-A1 | AN ANTIOXIDANT COMPOSITION COMPRISING A CINNAMIC ACID DERIVATIVE | BRAIN Biotech AG (DE) | 2026-04-29 | — | — | EP | disclosed |
| EP-4731617-A1 | USE OF DIHYDROPYRAN DERIVATIVES AS AROMA CHEMICALS | BASF SE (DE) | 2026-04-29 | — | — | EP | disclosed |
| EP-4728447-A1 | ENVIRONMENTAL ATTRIBUTES FOR AROMA CHEMICAL | BASF SE (DE) | 2026-04-22 | — | — | EP | disclosed |
| EP-4110277-B1 | COMPOSITIONS COMPRISING (BIO)-ALKANEDIOLS | SYMRISE AG (DE) | 2026-04-22 | — | — | EP | disclosed |
| US-20260096978-A1 | A METHOD FOR PREVENTING, MITIGATING AND/OR TREATING PTGS2-INDUCED SKIN DISORDERS AND RELATED DYSFUNCTIONS | SYMRISE AG (DE) | 2026-04-09 | — | — | US | disclosed |
| EP-4077299-B1 | SUBSTITUTED 4-METHYLENE-TETRAHYDROPYRANS, 4-METHYL-DIHYDROPYRANS AND 4-METHYL-TETRAHYDROPYRANS AND USE THEREOF AS AROMA CHEMICALS | BASF SE (DE) | 2026-04-01 | — | — | EP | disclosed |
| EP-4716732-A1 | USE OF ALKYL 4-ALKOXYPENTANOATES AS AROMA CHEMICALS | BASF SE (DE) | 2026-04-01 | — | — | EP | disclosed |
| EP-3045161-B1 | Use of active mixtures of 1,2-hexanediol and 1,2-octanediol in cosmetic, pharmaceutical or dermatological emulsions | SYMRISE AG (DE) | 2026-03-25 | — | — | EP | disclosed |
| US-20030053970-A1 | Deodorizing preparations | COGNIS IP MANAGEMENT GMBH (DE) | 2003-03-20 | — | — | US | disclosed |
| US-6534091-B1 | Microcapsules | COGNIS IBERIA S. L. (ES) | 2003-03-18 | — | — | US | disclosed |
| US-20030044441-A1 | Cosmetic preparations containing pearly lustre waxes in the form of dispersed systems | COGNIS DEUTSCHLAND GMBH & CO. KG (DE) | 2003-03-06 | — | — | US | disclosed |
| US-20030044469-A1 | Skincare agents | COGNIS IBERIA, S.L. (ES) | 2003-03-06 | — | — | US | disclosed |
| WO-2003009819-A2 | TEMPERATURE INSENSITIVE ONE-PHASE MICROEMULSIONS | DOW CORNING CORPORATION (US) | 2003-02-06 | — | — | WO | disclosed |
| US-20030003070-A1 | Use of nanoscale active anti-dandruff ingredients | COGNIS DEUTSCHLAND GMBH & CO. KG (DE) | 2003-01-02 | — | — | US | disclosed |
| US-6498197-B1 | Temperature insensitive one-phase microemulsions | DOW CORNING CORPORATION | 2002-12-24 | — | — | US | disclosed |
| US-20020010114-A1 | Water-based cleansing compositions | COGNIS DEUTSCHLAND GMBH & CO. KG (DE) | 2002-01-24 | — | — | US | disclosed |
| US-6313085-B1 | COMPOSITION COMPRISING ALKYL ETHER SULFATE AND ALKYL SULFATE HAVING HIGH SOLIDS CONTENT; PERSONAL CARE COMPOSITIONS | COGNIS DEUTSCHLAND GMBH (DE) | 2001-11-06 | — | — | US | disclosed |
| US-5980874-A | A SPRAYABLE, FINE-DROPLET, OIL-IN-WATER EMULSION COMPRISING WATER, NONIONIC EMULSIFIER, AN INORGANIC ASTRINGENT ANTIPERSPIRATION AGENT | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1999-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030044441-A1 | Cosmetic preparations containing pearly lustre waxes in the form of dispersed systems | LSS, LAGE3, LIPA | TSHR 1110/4885LMNA 1671/4885CA4 3812/4885 |
| US-20030044469-A1 | Skincare agents | RBP4, RBP1, CUTA | TSHR 2277/4885LMNA 208/4885CA4 2866/4885 |
| US-20030053970-A1 | Deodorizing preparations | LCT, DEK, LPO | TSHR 3238/4885LMNA 4516/4885CA4 83/4885 |
| US-20020010114-A1 | Water-based cleansing compositions | LIPA, WASHC4, WASHC5 | TSHR 3016/4885LMNA 3558/4885CA4 4035/4885 |
| US-20260096978-A1 | A METHOD FOR PREVENTING, MITIGATING AND/OR TREATING PTGS2-INDUCED SKIN DISORDERS AND RELATED DYSFUNCTIONS | PTGS2, PTGES2, PTGS1 | TSHR 1667/4885LMNA 2747/4885CA4 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.